Recruiting OBSERVATIONAL NCT06298565

A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa

Sponsor: argenx

Updated 7 times since 2024 Last updated: Feb 13, 2026 Started: Nov 4, 2024 Primary completion: Jun 30, 2034 Completion: Jun 30, 2034

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06298565, this observational or N/A phase trial focuses on Myasthenia Gravis and remains actively recruiting participants. Sponsored by argenx, it has been updated 7 times since 2024, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Feb 2026 — Present [monthly]

Recruiting
Dec 2025 — Feb 2026 [monthly]

Recruiting
May 2025 — Dec 2025 [monthly]

Recruiting
Jan 2025 — May 2025 [monthly]

Recruiting

Status: Not Yet Recruiting → Recruiting
Sep 2024 — Jan 2025 [monthly]

Not Yet Recruiting

▶ Show 2 earlier versions

Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting
Apr 2024 — Jul 2024 [monthly]

Not Yet Recruiting

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

argenx

Data source: argenx

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Altenburg, Germany , Austin, United States , Barcelona, Spain , Bergamo, Italy , Boca Raton, United States , Bochum, Germany , Bologna, Italy , Boston, United States , Charleston, United States , Detroit, United States and 22 more locations